Between Seroquel, Nexium and Crestor, AstraZeneca investors may have felt over the past few years that the extended fall off the patent cliff would never stop smarting. But the company promises things will turn around if they’ll just hang on.
Say what you want about AstraZeneca’s castoff strategy, but it helped drive another earnings beat for the lacking-in-sales drugmaker to kick off the year.
The whistle continues to blow in a case alleging AstraZeneca defrauded Medicare by playing down the risks of its antipsychotic drug Seroquel, just not as loudly.
AstraZeneca now has a one-stop shop for patients. It's a new all-in-one pharma app that offers savings card access, refill reminders and customer care contacts for the company's top brands.
AstraZeneca has prevailed: The first jury to hear a Seroquel case decided that the warnings on its label were adequate, so patients and doctors should have had enough information about the drug's
